Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL987068 | 0.90 | DHFR (0.38) | DHFR | |
| SCHEMBL988729 | 0.89 | MEN1 (0.35) | DHFRMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL988728 | 0.89 | MEN1 (0.35) | DHFRMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL988271 | 0.88 | DHFR (0.37) | DHFR | |
| SCHEMBL988272 | 0.88 | DHFR (0.37) | DHFR | |
| SCHEMBL15180114 | 0.84 | ALDH1A1 (0.41) | MEN1ALDH1A1MAPTKMT2AHSD17B10 | |
| SCHEMBL10209682 | 0.83 | MEN1 (0.34) | DHFRMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL10209681 | 0.83 | MEN1 (0.34) | DHFRMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL990715 | 0.83 | MEN1 (0.34) | DHFRMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3219438 | 0.83 | MEN1 (0.34) | DHFRMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213664-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| US-8552016-B2 | Anti-cancer cyclopenta(g)quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2013-10-08 | — | — | US | disclosed |
| US-8486955-B2 | Anti-cancer cyclopenta [g] quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2013-07-16 | — | — | US | disclosed |
| US-8063056-B2 | Anti-cancer cyclopenta [g]quinazonline compounds | BTG INTERNATIONAL LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| EP-1421069-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| EP-2332962-A1 | Cyclopenta[g]quinazoline compounds for use in the treatment of inflammatory or allergic conditions | BTG International Limited (GB) | 2011-06-15 | — | — | EP | disclosed |
| EP-2311850-A1 | Anti-cancer cyclopenta[g]quinazoline compounds | BTG International Limited (GB) | 2011-04-20 | — | — | EP | disclosed |
| US-7863284-B2 | Anti-cancer cyclopenta[G]quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2011-01-04 | — | — | US | disclosed |
| US-20100273817-A1 | Anti-cancer cyclopenta(g)quinazoline compounds | BGT International Limited (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-1421105-B1 | ANTI-CANCER CYCLOPENTA¬G QUINAZOLINE COMPOUNDS | BTG INT LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| US-7705006-B2 | Anti-cancer cyclopenta[g]quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-20100056551-A1 | Anti-cancer cyclopenta [G] quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-7297701-B2 | Anti-cancer cyclopenta [G]quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2007-11-20 | — | — | US | disclosed |
| US-7250511-B2 | Process for the preparation of cyclopenta[g]quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| US-20040266798-A1 | Process for the preparation of cyclopenta[g]quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
| US-20040242606-A1 | Anti-cancer cyclopenta (g)quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1421105-A1 | ANTI-CANCER CYCLOPENTA[G]QUINAZOLINE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2004-05-26 | — | — | EP | disclosed |
| EP-1421069-A1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG International Limited (GB) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003020748-A1 | ANTI-CANCER CYCLOPENTA[G]QUINAZOLINE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020706-A1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[g]QUINAZOLINE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056551-A1 | Anti-cancer cyclopenta [G] quinazoline compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NR0B1, CNR1 | DHFR 1345/4885MEN1 2467/4885ALDH1A1 1202/4885 |
| US-20100273817-A1 | Anti-cancer cyclopenta(g)quinazoline compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR1, NR0B1 | DHFR 1294/4885MEN1 2455/4885ALDH1A1 1231/4885 |
| US-20040266798-A1 | Process for the preparation of cyclopenta[g]quinazoline derivatives | COX6A1, MT-ND6, CYP2D6 | DHFR 2726/4885MEN1 2322/4885ALDH1A1 1243/4885 |
| US-20040242606-A1 | Anti-cancer cyclopenta (g)quinazoline compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, NR4A1 | DHFR 1522/4885MEN1 3729/4885ALDH1A1 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.